Site work and new construction of a laboratory facility in Hamilton, Ontario. Completed plans call for the construction of a 372,970-square-foot, four-story above grade laboratory facility; and for site work for a laboratory facility.

McMaster Innovation Park (MIP) has selected the progressive Design-Build (DB) Stipulated Price method to design and construct a new state-of-the-art biotechnology process and manufacturing lab and office facility at Longwood Road South at Aberdeen Avenue in Hamilton, Ontario. This Request for Proposal (RFP) is to solicit proposals from pre-qualified design build proponents for the design and construction of the OmniaBio Manufacturing Complex identified in the Proposed Master Plan. Owner only provides plans and specs to their prequalified contractors. Interested sub trades, manufacturers and suppliers should contact the prequalified contractors. More information may be obtained at: https://mcmasterinnovationpark.bidsandtenders.ca Notes: Building on their legacy in Health Sciences globally, Multiplex Canada has signed an Integrated Project Delivery (IPD) contract to deliver the OmniaBio B project for McMaster Innovation Park (MIP) and their tenant CCRM . This ultra fast-track project is the first component of the master planned McMaster Innovation Park in Hamilton, Ontario, and will be delivered by an IPD Team comprised of Colliers Project Leaders, IBI Group, Arup Canada, McCallum Sather, Guild Electric Limited, Sprint Mechanical Inc., Flynn Canada, Walters Inc., and Multiplex. McMaster Innovation Park is designed with a focus on sustainability and the environment at its core. The park is the bridge between research and industry, creating an ecosystem built on diversity to drive innovation and success to benefit the research, business, startups and community. Multiplex is known for their collaborative approach and ability to maintain a shared focus on each project they deliver. They are an IPD partner that combines leading edge digital technology with world-class construction expertise. Multiplex will deliver the core and shell as part of the first phase of the project that when completed, will span 119,000 square feet over three storeys. Its final design will feature clean rooms, specialized labs, offices and cGMP compliant manufacturing. The OmniaBio B project will achieve not only significant sustainable building milestones, but it will also be the first cutting-edge cell and gene therapy facility in Canada "We are excited to work with a world class client and industry leading planners, consultants and trades on this project. We are certain that OmniaBio B will become the benchmark and encourage life-sciences to thrive in Ontario," shares Terry Olynyk, President and Managing Director at Multiplex Canada. Early works commenced at the end of Q2 2022.